Capricor Therapeutics (CAPR) Competitors $7.67 -0.03 (-0.39%) Closing price 04:00 PM EasternExtended Trading$7.68 +0.01 (+0.20%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CAPR vs. APGE, IMCR, DYN, CDTX, TWST, TVTX, BHVN, AUPH, SDGR, and EVOShould you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Apogee Therapeutics (APGE), Immunocore (IMCR), Dyne Therapeutics (DYN), Cidara Therapeutics (CDTX), Twist Bioscience (TWST), Travere Therapeutics (TVTX), Biohaven (BHVN), Aurinia Pharmaceuticals (AUPH), Schrodinger (SDGR), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry. Capricor Therapeutics vs. Its Competitors Apogee Therapeutics Immunocore Dyne Therapeutics Cidara Therapeutics Twist Bioscience Travere Therapeutics Biohaven Aurinia Pharmaceuticals Schrodinger Evotec Capricor Therapeutics (NASDAQ:CAPR) and Apogee Therapeutics (NASDAQ:APGE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk. Is CAPR or APGE more profitable? Apogee Therapeutics has a net margin of 0.00% compared to Capricor Therapeutics' net margin of -181.71%. Apogee Therapeutics' return on equity of -34.65% beat Capricor Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Capricor Therapeutics-181.71% -62.71% -50.82% Apogee Therapeutics N/A -34.65%-32.76% Do analysts prefer CAPR or APGE? Capricor Therapeutics currently has a consensus target price of $22.56, suggesting a potential upside of 194.08%. Apogee Therapeutics has a consensus target price of $99.00, suggesting a potential upside of 171.90%. Given Capricor Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Capricor Therapeutics is more favorable than Apogee Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capricor Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Apogee Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Do insiders & institutionals hold more shares of CAPR or APGE? 21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 10.5% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 42.8% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, CAPR or APGE? Capricor Therapeutics has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Does the media prefer CAPR or APGE? In the previous week, Capricor Therapeutics had 46 more articles in the media than Apogee Therapeutics. MarketBeat recorded 53 mentions for Capricor Therapeutics and 7 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of -0.07 beat Capricor Therapeutics' score of -0.23 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 3 Very Positive mention(s) 6 Positive mention(s) 23 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Apogee Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings and valuation, CAPR or APGE? Capricor Therapeutics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapricor Therapeutics$22.27M15.75-$40.47M-$1.64-4.68Apogee TherapeuticsN/AN/A-$182.15M-$4.13-8.82 SummaryCapricor Therapeutics beats Apogee Therapeutics on 9 of the 16 factors compared between the two stocks. Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPR vs. The Competition Export to ExcelMetricCapricor TherapeuticsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$352.02M$10.67B$5.73B$9.80BDividend YieldN/A1.90%4.54%4.08%P/E Ratio-4.6820.1830.7425.12Price / Sales15.7528.04441.05108.85Price / CashN/A24.7437.3459.16Price / Book3.333.388.886.24Net Income-$40.47M$209.94M$3.26B$265.56M7 Day Performance-4.60%1.01%1.73%0.90%1 Month Performance11.48%9.97%3.54%1.88%1 Year Performance88.92%-11.39%28.63%20.09% Capricor Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPRCapricor Therapeutics3.0174 of 5 stars$7.67-0.4%$22.56+194.1%+94.4%$352.02M$22.27M-4.68101Trending NewsAPGEApogee Therapeutics3.5583 of 5 stars$34.65-2.1%$99.00+185.7%-18.5%$1.63BN/A-9.6391IMCRImmunocore1.9315 of 5 stars$31.89-0.3%$58.00+81.9%-11.2%$1.61B$310.20M-79.73320Positive NewsDYNDyne Therapeutics3.286 of 5 stars$11.24+0.7%$34.94+210.8%-72.8%$1.59BN/A-2.91100CDTXCidara Therapeutics3.3689 of 5 stars$62.00flat$64.14+3.5%+394.4%$1.57B$1.27M-5.5790TWSTTwist Bioscience4.0645 of 5 stars$27.63+7.8%$49.40+78.8%-35.7%$1.55B$312.97M-19.06990Positive NewsTVTXTravere Therapeutics2.5414 of 5 stars$17.28+2.0%$32.21+86.4%+116.2%$1.51B$233.18M-8.47460Analyst UpgradeBHVNBiohaven3.7923 of 5 stars$13.42-8.9%$58.46+335.5%-58.5%$1.51BN/A-1.43239Trending NewsAnalyst ForecastAUPHAurinia Pharmaceuticals2.2158 of 5 stars$11.43+0.5%$12.00+5.0%+95.2%$1.50B$235.13M26.58300SDGRSchrodinger3.1638 of 5 stars$18.63-3.0%$32.75+75.8%+1.6%$1.41B$207.54M-7.51790Analyst ForecastEVOEvotec1.7358 of 5 stars$3.81-3.1%$5.90+54.9%+12.9%$1.40B$862.40M0.004,827Analyst Revision Related Companies and Tools Related Companies APGE Competitors IMCR Competitors DYN Competitors CDTX Competitors TWST Competitors TVTX Competitors BHVN Competitors AUPH Competitors SDGR Competitors EVO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CAPR) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access